Table 2. Unfavorable factors affecting PFS and OS in 217 patients with advanced-stage EOC.
| Factors | Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | Adjusted HR | 95% CI | p-value | ||
| PFS | |||||||
| Age ≤54 (yr) | 0.909 | 0.670–1.233 | 0.540 | - | - | - | |
| FIGO stage IV disease | 1.476 | 1.034–2.106 | 0.032 | - | - | - | |
| Grade 3 disease | 0.827 | 0.564–1.213 | 0.331 | - | - | - | |
| Non-serous type | 1.067 | 0.747–1.524 | 0.721 | - | - | - | |
| Suboptimal debulking surgery | 1.710 | 1.260–2.322 | 0.001 | 1.675 | 1.169–2.400 | 0.005 | |
| No neoadjuvant chemotherapy | 0.781 | 0.545–1.119 | 0.178 | - | - | - | |
| Fibrinogen >485.2 (mg/dL) | 1.590 | 1.172–2.157 | 0.003 | 1.389 | 0.979–1.972 | 0.066 | |
| CA-125 >4,442.5 (U/mL) | 1.373 | 0.936–2.015 | 0.105 | - | - | - | |
| NLR >4.46 | 0.910 | 0.665–1.246 | 0.557 | - | - | - | |
| PLR >293.66 | 1.164 | 0.851–1.592 | 0.341 | - | - | - | |
| OS | |||||||
| Age ≤54 (yr) | 0.813 | 0.561–1.178 | 0.274 | - | - | - | |
| FIGO stage IV disease | 1.493 | 0.982–2.270 | 0.061 | - | - | - | |
| Grade 3 disease | 1.586 | 1.003–2.508 | 0.048 | - | - | - | |
| Non-serous type | 1.387 | 0.924–2.083 | 0.115 | - | - | - | |
| Suboptimal debulking surgery | 2.105 | 1.439–3.080 | <0.001 | 2.124 | 1.374–3.283 | 0.001 | |
| No neoadjuvant chemotherapy | 1.009 | 0.633–1.609 | 0.968 | - | - | - | |
| Fibrinogen >485.2 (mg/dL) | 1.627 | 1.124–2.354 | 0.010 | 1.581 | 1.032–2.423 | 0.035 | |
| CA-125 >4,442.5 (U/mL) | 1.064 | 0.668–1.696 | 0.794 | - | - | - | |
| NLR >4.46 | 1.198 | 0.824–1.741 | 0.345 | - | - | - | |
| PLR >293.66 | 1.544 | 1.065–2.237 | 0.022 | - | - | - | |
EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; NLR, neutrophil to lymphocyte ratio; OS, overall survival; PFS, progression-free survival; PLR, platelet to lymphocyte ratio.